Stocks in Focus

MICUBE SOLUTION, INC. Posts “Two Consecutive Up Days” on News of Selection for Government-Funded Project [Featured Stock]

Shin Ha-yeon
2026-09-03 09:07:29
[Edaily Reporter Shin Ha-yeon ] MICUBE SOLUTION, INC.(373170)has hit the daily price limit for two consecutive trading days. It appears that buying interest is surging following news that the company has been selected for two government-funded projects.
(Photo: MICUBE SOLUTION, INC.)

According to MP Doctor on the 3rd, as of 9:05 a.m. today, MICUBE SOLUTION, INC. is trading at 2,870 won, up 29.86% from the previous trading day.
Previously, on the previous day, MICUBE SOLUTION, INC. announced that it had been selected for two government-funded projects under the “Project to Foster an R&D Ecosystem for Physical AI-Based Software Platforms,” organized by the Ministry of Science and ICT and the National IT Industry Promotion Agency.
The two projects are “Standardization of Collaborative Intelligence Physical AI Software and Design and Construction of a Modular SDF-OCS” and “Development of Physical AI-Digital Twin Virtual Environment Technology.” The research period is a total of 53 months, from August 1, 2026, to December 31, 2030. MICUBE SOLUTION, INC. has been allocated a total of 6.1 billion won in government-funded R&D grants.

Economy

Corporation

IT·Science

Economy

[Exclusive] Financial Supervisory Service Launches Sudden Investigation into Three Credit Rating Agencies Over “Belated Downgrades”… Scrutinizing JR and Joongang for Neglecting Default Risks

The Financial Supervisory Service (FSS) has launched a surprise on-site investigation into the three major domestic credit rating agencies in connection with the series of defaults by JR GLOBAL REIT a…
2026-09-11 12:12:02

Corporation

'Loresibint Under Review for Approval in the U.K. Following U.S. Approval'… SamilPharmaceutical Gets Green Light to Enter 8 Trillion Won Korean Market

SamilPharmaceutical(000520)With “Lorecivivint,” a new drug for osteoarthritis for which BioSplice holds exclusive domestic distribution rights, entering the regulatory review process in the UK followi…
2026-09-11 10:02:02

IT·Science

GC Biopharma Corp. Receives IND Approval for Phase 2 Clinical Trial of COVID-19 mRNA Vaccine… First Patient to Receive Dose by Year-End

GC Biopharma Corp. Headquarters in Yongin, Gyeonggi Province (Photo: GC Biopharma Corp.) GC Biopharma Corp. will begin Phase 2 clinical trials of its COVID-19 vaccine, which utilizes the company’s…
2026-09-11 14:35:03